These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38008108)

  • 1. Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
    Moussa S; Netchiporouk E
    Lancet; 2024 Jan; 403(10422):118-119. PubMed ID: 38008108
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.
    Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P
    Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841
    [No Abstract]   [Full Text] [Related]  

  • 3. Ligelizumab for the treatment of chronic spontaneous urticaria.
    Wedi B
    Expert Opin Biol Ther; 2020 Aug; 20(8):853-861. PubMed ID: 32380864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series.
    Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440
    [No Abstract]   [Full Text] [Related]  

  • 5. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.
    Holm JG; Sørensen JA; Thomsen SF
    Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086
    [No Abstract]   [Full Text] [Related]  

  • 6. Ligelizumab for chronic spontaneous urticaria.
    Sabroe RA
    Br J Dermatol; 2020 Nov; 183(5):829-830. PubMed ID: 32002982
    [No Abstract]   [Full Text] [Related]  

  • 7. High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?
    Türk M; Yılmaz İ
    Int Arch Allergy Immunol; 2021; 182(5):461-462. PubMed ID: 33321510
    [No Abstract]   [Full Text] [Related]  

  • 8. Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria.
    Muntyanu A; Ouchene L; Ben-Shoshan M; Netchiporouk E
    J Cutan Med Surg; 2020; 24(2):201-202. PubMed ID: 32208012
    [No Abstract]   [Full Text] [Related]  

  • 9. Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.
    Staubach P; Alvaro-Lozano M; Sekerel BE; Maurer M; Ben-Shoshan M; Porter M; Hua E; Ji Y; Burciu A; Savelieva M; Severin T; Drollmann A; Bienczak A
    Pediatr Allergy Immunol; 2023 Jul; 34(7):e13982. PubMed ID: 37492920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis.
    Karstarli Bakay OS; Kacar N
    Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106
    [No Abstract]   [Full Text] [Related]  

  • 11. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.
    Maurer M; Giménez-Arnau A; Bernstein JA; Chu CY; Danilycheva I; Hide M; Makris M; Metz M; Savic S; Sitz K; Soong W; Staubach P; Sussman G; Barve A; Burciu A; Hua E; Janocha R; Severin T
    Allergy; 2022 Jul; 77(7):2175-2184. PubMed ID: 34773261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatments for chronic urticaria.
    Kolkhir P; Altrichter S; Munoz M; Hawro T; Maurer M
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):2-12. PubMed ID: 31446134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 15. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies.
    Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review.
    Errichetti E; Stinco G
    Dermatol Ther; 2021 Mar; 34(2):e14821. PubMed ID: 33506984
    [No Abstract]   [Full Text] [Related]  

  • 17. Dupilumab as a rescue therapy for a chronic urticaria patient who showed secondary failure to omalizumab.
    Sun Y; Lin SY; Lan CE
    Kaohsiung J Med Sci; 2022 Jun; 38(6):610-611. PubMed ID: 35394689
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
    Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S
    JAMA Dermatol; 2021 Nov; 157(11):1316-1327. PubMed ID: 34431983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Updated Therapeutic Strategy for Chronic Idiopathic Urticaria.
    Adusumilli NC; Friedman AJ
    J Drugs Dermatol; 2021 Mar; 20(3):354-355. PubMed ID: 33683088
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
    Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.